Physician profile
Jill M Mitchell
NPI 1457585002
$5,773.67
in general payments reported to CMS, 2019-2025
30 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $545 · 2021: $1,030 · 2022: $834 · 2023: $887 · 2024: $938 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Education: $99.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.22 |
| Education | $99.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $613.86 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $603.84 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $551.23 | 2020-2024 | Acthar |
| Vifor Pharma, INC. | $408.84 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $394.22 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $332.59 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $314.72 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $277.03 | 2021-2025 | |
| Horizon Therapeutics Plc | $267.29 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $218.63 | 2022-2025 | |
| Akebia Therapeutics INC | $207.96 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $190.18 | 2019-2024 | Korsuva, Velphoro |
| Novartis Pharmaceuticals Corporation | $182.06 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $161.70 | 2019 | |
| Aurinia Pharma U.S., INC. | $155.95 | 2021-2024 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $144.67 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.62 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $102.81 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $94.81 | 2019-2020 | |
| Genzyme Corporation | $84.49 | 2019-2021 | |
| Nxstage Medical, INC. | $58.54 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $51.81 | 2019-2023 | Rayaldee |
| Janssen Pharmaceuticals, INC | $41.51 | 2019 | |
| Novo Nordisk INC | $39.44 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $32.19 | 2025 | Keveyis |
| Cormedix INC. | $25.49 | 2024 | Defencath |
| Shire North American Group INC | $24.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.96 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.17 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.